FIGURE 1 from Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC

A,EML4-ALK variant type observed in clinical and liquid biopsy cohorts. B, Clinically relevant somatic co-mutations observed in clinical and liquid biopsy (LB) cohorts. Copy-number deletion/loss not reported in the liquid biopsy cohort; loss-of-function mutations in CDKN2A/B, PTEN, and CTNNB1 are included.